ESCRS - $2.2 million raised to build VR tools for amblyopia

$2.2 million raised to build VR tools for amblyopia

Treatment for binocular vision disorders is available at more than 90 clinics across the world.

$2.2 million raised to build VR tools for amblyopia
Colin Kerr
Colin Kerr
Published: Tuesday, May 23, 2017
[caption id="attachment_8371" align="alignnone" width="800"]Image Credit: Vivid Vision Image Credit: Vivid Vision[/caption] Medical technology company Vivid Vision has announced that it has raised $2.2 million to build Virtual Reality (VR) tools that could be used to treat amblyopia. The company says its VR treatment for binocular vision disorders is available at more than 90 clinics across the world. Founded in 2014, Vivid Vision applies virtual reality to the field of vision care. Its founder and CEO, James Blaha, a programmer and lifelong sufferer of amblyopia, started the company after experimenting on himself. Before building the first prototype, Blaha couldn’t read with his weak eye or see in 3D. Since then, according to Vivid Vision, the vision in Blaha’s weak eye has improved to nearly 20/20. Vivid Vision launched its clinical vision therapy suite in late 2015 for optometrists and ophthalmologists and since then, the 90 clinics using it have treated more than 6,000 patients. On average, treatment lasts eight months, with patients coming one or two times a week to use the VR system. www.seevividly.com “It is a unique, far more efficient solution to treat Amblyopia, as well as a wide array of binocular vision dysfunction,” said Dan Fortenbacher, founder of Wow Vision Therapy, which has two locations in Michigan. “The progress the patient makes in breaking through suppression and developing 3D vision has been remarkable with Vivid Vision.”
Tags: amblyopia
Latest Articles
Simulators Benefit Surgeons and Patients

Helping young surgeons build confidence and expertise.

Read more...

Diamonds in the Rough

The push for inclusivity in ophthalmology.

Read more...

Making Female Leadership More than a Moment

A remarkable global confluence of women in key positions.

Read more...

ESCRS Talks Technology at AAO

Europe adopts technological advances, US still waiting for lenses and lasers.

Read more...

Sorting Out Simultaneous Vision IOLs

The ESCRS Eye Journal Club discuss a new landmark paper on IOL classification and the need for harmonisation of terminology for presbyopic IOLs.

Read more...

Big Advantages to Small-Aperture IOLs

Small-aperture IOLs offer superior image quality with increased range of focus.

Read more...

Prioritising Self-Care

Benefits of maintaining physical, emotional, and mental health extend beyond the personal sphere.

Read more...

Valuing Clinical Trial Design

How inclusivity and diversity can enhance scientific accuracy in research.

Read more...

Knowing Iris Repair: Using Iridodiathermy in Iris Surgery

Prepare for decentred pupils and uneven irides in multiple situations.

Read more...

Neuroprotectant Treatment for MacTel Type 2

Intravitreal implant releasing ciliary neurotrophic factor found safe and effective in pivotal trials.

Read more...